AUG 25·SEC EDGARLow
Chao Xingjuan sold $146K of CBLL
Chao Xingjuan (President and CEO) sold 6,068 shares of Ceribell, Inc. (CBLL) at $24.02 ($0.15M total) on 2026-08-21.
StockNASDAQ · US · USDHealthcare · Medical Devices
$CBLL
Ceribell, Inc.
Price · $CBLLvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $CBLL in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $2.3M 11 txs
Blumberg Scott3× · $900K
10b5-1 share of filings55%
Top stories · $CBLLMore →
AUG 21·SEC EDGAR
Blumberg Scott sold $864K of CBLL
Blumberg Scott (Chief Financial Officer) sold 34,502 shares of Ceribell, Inc. (CBLL) at an average of $25.03 ($25.00–$25.03, $0.86M total) across 2 trades over 2026-08-18 to 2026-08-19 under a Rule 10b5-1 trading plan.
AUG 20·SEC EDGAR
Chao Xingjuan sold $841K of CBLL
Chao Xingjuan (President and CEO) sold 33,614 shares of Ceribell, Inc. (CBLL) at an average of $25.03 ($25.00–$25.03, $0.84M total) across 2 trades over 2026-08-18 to 2026-08-19 under a Rule 10b5-1 trading plan.
CBLL sentiment & insider activity
Recent CBLL coverage spans insider activity, regulation and financial news.
In the last 30 days, CBLL insiders filed 11 SEC Form 4 transactions — no purchases and 11 sales ($2.3M). The most active reporter was Blumberg Scott, Chief Financial Officer, with 3 filings. 55% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving CBLL
The sale modestly reduces insider ownership but is unlikely to move the stock materially.
Insider sale may signal reduced confidence, potentially pressuring the stock short‑term.
The insider sale may signal confidence concerns but size is modest relative to float.
Regulatory clearance for product enhancements can improve adoption prospects for point-of-care seizure assessment.
This is a routine insider open-market sale with no 10b5-1 plan disclosed, which can modestly affect near-term sentiment but is not a fundamental catalyst by itself.
alphai scores every news story that mentions CBLL with an AI model for sentiment and relevance, and aggregates insider trades from Ceribell, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $CBLL
Score
Chao Xingjuan sold $146K of CBLL
Chao Xingjuan (President and CEO) sold 6,068 shares of Ceribell, Inc. (CBLL) at $24.02 ($0.15M total) on 2026-08-21.
1 min readBlumberg Scott sold $864K of CBLL
Blumberg Scott (Chief Financial Officer) sold 34,502 shares of Ceribell, Inc. (CBLL) at an average of $25.03 ($25.00–$25.03, $0.86M total) across 2 trades over 2026-08-18 to 2026-08-19 under a Rule 10b5-1 trading plan.
1 min readChao Xingjuan sold $841K of CBLL
Chao Xingjuan (President and CEO) sold 33,614 shares of Ceribell, Inc. (CBLL) at an average of $25.03 ($25.00–$25.03, $0.84M total) across 2 trades over 2026-08-18 to 2026-08-19 under a Rule 10b5-1 trading plan.
1 min readWeekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals
Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
7 min readTaylor Joseph Michael sold $306K of CBLL
Taylor Joseph Michael sold 13,095 shares of Ceribell, Inc. (CBLL) at $23.40 ($0.31M total) on 2026-08-13.
1 min readCeribell, Inc. (CBLL): Results of Operations and Financial Condition
Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor
6 min readCeribell Secures FDA Clearance For Advanced EEG AI Enhancements
Ceribell (CBLL) said the U.S. FDA granted 510(k) clearance for two AI enhancements in its cloud Neurology Portal: epileptiform abnormality detection and artifact reduction. The company says the updates improve EEG signal interpretation and reduce review time. CBLL shares closed Aug. 7, 2026 at $18.81, up 3.07%.
4 min readChao Xingjuan sold $714K of CBLL
Chao Xingjuan (President and CEO) sold 39,000 shares of Ceribell, Inc. (CBLL) at $18.32 ($0.71M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
1 min readCeriBell stock rises after securing Medicare payment approval
CeriBell Inc. (NASDAQ:CBLL) shares rose about 3% after CMS approved a New Technology Add-on Payment for its Delirium Monitor System. The NTAP allows up to $2,171 per eligible Medicare patient case, starting Oct. 1, 2026, following FDA 510(k) clearance in Dec. 2025.
3 min readCeribell, Inc. (CBLL): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective July 28, 2026, the Board of Directors (the “Board”) of CeriBell, Inc. (the “Company”), in order to achieve a more
3 min read